Leeds research points to new therapy for hepatitis C treatment

December 09, 2008

Combination therapies similar to those used for HIV patients may be the best way of treating hepatitis C virus (HCV), say researchers from the University of Leeds.

A study of a protein called p7, has revealed that differences in the genetic coding of the protein between virus strains - known as genotypes - alter the sensitivity of the virus to drugs that block its function.

The p7 protein assists the spread of HCV around the body and is a promising target for new drug treatments for the virus. Its role was discovered in 2003 by Dr Steve Griffin with Professors Mark Harris and Dave Rowlands of the University's Faculty of Biological Sciences. In laboratory tests their latest research shows that inhibiting p7 with drugs can prevent the spread of HCV..

"One of the challenges in finding treatments for viruses is their ability to constantly change their genetic makeup," says Professor Harris. "Our research shows there can't be a one-size-fits-all approach to treating HCV with p7 inhibitors in the future. We believe combination treatments will work much more efficiently, as they take into account the variability of the p7 protein."

Approximately 180 million people worldwide are infected by HCV, which causes inflammation of the liver and can lead to liver failure or liver cancer. Spread by contact with infected blood or other bodily fluids, there is no vaccine against the disease which is largely asymptomatic in its early stages. The disease is currently treated with broad spectrum, non-specific anti-viral drugs.

Dr Griffin and Prof. Harris examined the response of HCV to a panel of compounds including the well known anti-viral drug, rimantadine, which targets a similar protein in the flu virus. They found that the drug's effectiveness was altered depending on the genetic makeup of the p7 protein.

"We 'borrowed' rimantadine to test its effects because p7 behaves similarly to a protein found in the flu virus," says Dr Griffin. " Although rimantadine works well in the laboratory, we now need to develop new drugs specifically targeted against p7 that we can take forward for future therapies."

University of Leeds

---

---

	Inhaled Zanamivir Beats Rimantadine.: An article from: Family Practice News by Mitchel L. Zoler (Author) This digital document is an article from Family Practice News, published by International Medical News Group on January 1, 2001. The length of the article is 389 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Inhaled Zanamivir Beats Rimantadine. Author: Mitchel L. Zoler Publication: Family Practice News (Magazine/Journal) Date: January 1, 2001 Publisher: International Medical News Group Volume: 31 Issue: 1 Page: 18 Distributed by Thomson...
	Rimantadine by Book on Demand Pod (Publisher)
	Rimantadine by Ronald Cohn Jesse Russell (Author) High Quality Content by WIKIPEDIA articles! Rimantadine (INN, sold under the trade name Flumadine) is an orally administered antiviral drug used to treat, and in rare cases prevent, influenzavirus A infection. When taken within one to two days of developing symptoms, rimantadine can shorten the duration and moderate the severity of influenza. Both rimantadine and the similar drug amantadine are derivates of adamantane. Rimantadine was approved by the Food and Drug Administration (FDA) in 1994. This book was created using print-on-demand technology.
	New Flu Drugs vs. Older Flu Drugs.(Brief Article)(Statistical Data Included): An article from: Family Practice News by Doug Brunk (Author) This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2000. The length of the article is 1040 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: New Flu Drugs vs. Older Flu Drugs.(Brief Article)(Statistical Data Included) Author: Doug Brunk Publication: Family Practice News (Magazine/Journal) Date: February 1, 2000 Publisher: International Medical News Group Volume: 10 Issue: 3 Page: 46 Article Type: Brief Article, Statistical Data Included Distributed by Thomson...
	Contagion by Robin Cook (Author) One of Cook's most successful--and timely—bestsellers. Contagion is a terrifying cautionary tale for the millennium as a deadly epidemic is spread not merely by microbes—but by sabotage...
	Influenza Virology: Current Topics by Yoshihiro Kawaoka (Editor) Three times in the last century, influenza viruses have undergone major genetic changes resulting in global pandemics that had devastating effects. The most infamous pandemic was the "Spanish Flu" which affected up to 25% of the world population and is thought to have killed at least 40 million people. In 1997 and 2003, a new influenza A virus of H5N1 subtype emerged in Asia and was transmitted directly from birds to humans with lethal outcomes. Despite monumental efforts to contain them, the H5N1 viruses expanded their territory and caused a major outbreak in wild waterfowl in China in 2005. Despite extensive, coordinated efforts by various agencies and disciplines, both national and international, we are ill-equipped for a new influenza pandemic. In fact, it is highly unlikely that...
	Viral Infections of the Respiratory Tract (Lung Biology in Health and Disease) by Raphael Dolin (Editor) This groundbreaking reference outlines the clinical manifestations and management of illness caused by common respiratory viruses, and details the most up-to-date diagnostic, therapeutic, and preventative measures. Reviews specific pulmonary diseases on a pathogen-by-pathogen basis! Assessing the newest approaches to viral diagnosis, Viral Infections of the Respiratory Tract · analyzes important interactions between viruses and the respiratory tract · elucidates the pathophysiology and unique mechanisms by which viruses cause illness and evade host defense mechanisms · covers the clinical management of respiratory viral infections · shows how viruses can be used for understanding pulmonary diseases such as bronchiolitis, asthma, and secondary bacterial infections of the lung ...
	Blueprints Notes and Cases: Pharmacology by Katherine Y. Yang (Author), Larissa Graff (Author), Aaron B. Caughey (Author) If you are wondering how the pharmacology principles you are studying will apply to real life patients, Blueprints Notes & Cases—Pharmacology has just what you need—basic science concepts tied to clinical cases! This book offers high-yield, concise basic science content presented in a logical template. Each topic features a case presentation followed by thought questions and a basic science review. Thumbnails and key points provide a quick review of the essential information. Multiple-choice questions at the end of each case allow you to test your knowledge. Blueprints Notes & Cases—Pharmacology is perfect for medical students. Use it during your coursework to aid in understanding application of principles, then review again as you prep for exams. Physician assistants, nurse...
	Practical Guidelines in Antiviral Therapy by George J. Galasso (Editor) This text was developed with the practicing physician in mind, however, it will be of considerable interest to the virologist, pharmacologist, chemist and all scientists interested in antiviral agents. Progress in the field of antiviral development is now moving rapidly and there is hope that one day there will be successful treatment modalities for most viral diseases. This work contains contributions from experts around the world, capturing worldwide practices. An online version providing the current status of antiviral research is planned for the near future.
	Antiviral Agents, Vaccines and Immunotherapies (Infectious Disease and Therapy) by Stephen Tyring (Editor) Unlike any other source on the subject, Antiviral Agents, Vaccines, and Immunotherapies analyzes the benefits and limitations of every available drug, vaccine, and immunotherapy utilized in the prevention and control of viral diseases. This reference provides in-depth reviews of more than 50 drugs and antiviral agents for HIV, human herpesviruses, human papillomaviruses (HPV), influenza, respiratory syncytial virus, hepatitis B, and analyzes their mechanisms of action, dosage, side effects, and drug resistance. The book also provides an overview of the use of immunoglobulins and monoclonal antibodies for antiviral use and supplies extensive references, tables, and figures throughout the text.